Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736661 | 0.77 | NR4A2 (0.50) | NR4A2AKR1C3KMT2AMEN1NR1H4 | |
| SCHEMBL27855061 | 0.77 | ALDH1A1 (0.60) | CRHBPCRHR2KMT2A | |
| SCHEMBL1736660 | 0.76 | NR4A2 (0.49) | NR4A2AKR1C3KMT2AMEN1NR1H4 | |
| SCHEMBL6379614 | 0.76 | KMT2A (0.62) | AKR1C3KMT2AMEN1USP2 | |
| SCHEMBL11165331 | 0.74 | CRHBP (0.65) | CRHBPCRHR2KMT2AMEN1MAPT | |
| Benzoic Acid SCHEMBL28072652 | 0.74 | CYP19A1 (0.65) | NR4A2KMT2ASRD5A2 | |
| SCHEMBL10265065 | 0.73 | ATM (0.73) | KMT2AMEN1MAPT | |
| SCHEMBL12568577 | 0.73 | CYP19A1 (0.46) | CRHBPCRHR2KMT2AMEN1MAPT | |
| SCHEMBL6693659 | 0.72 | AKR1C3 (0.56) | NR4A2AKR1C3KMT2AMRGPRX4 | |
| SCHEMBL4250289 | 0.72 | KMT2A (0.61) | NR4A2AKR1C3KMT2AMEN1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018567-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF BETA-LACTAMASES | BECTON DICKINSON CO (US) | 2024-01-18 | — | — | US | claimed |
| US-11572579-B2 | Kits for the detection of beta-lactamases | BECTON, DICKINSON AND COMPANY (US) | 2023-02-07 | — | — | US | claimed |
| US-12544395-B2 | Combination compositions comprising a beta-lactamase inhibitor and uses thereof | VenatoRx Pharmaceuticals, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-3886798-B1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | VENATORX PHARMACEUTICALS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12460245-B2 | Luciferase sequences utilizing infrared-emitting substrates to produce enhanced luminescence | PROMEGA CORPORATION (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250321227-A1 | DUAL-MODE ELECTROCHEMICAL POINT-OF-CARE DETECTION, QUANTIFICATION AND PROFILING OF PATHOGENS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (IL) | 2025-10-16 | — | — | US | disclosed |
| US-20250281465-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| EP-4608436-A1 | CONSTRUCTS AND THEIR USE | Nykode Therapeutics ASA (NO) | 2025-09-03 | — | — | EP | disclosed |
| EP-4583895-A1 | SYSTEMS FOR PRODUCTION OF TRANSDUCING PARTICLES, METHODS, KITS, COMPOSITIONS AND USES THEREOF | Trobix Bio Ltd (IL) | 2025-07-16 | — | — | EP | disclosed |
| US-20250171555-A1 | HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF | Visterra, Inc. | 2025-05-29 | — | — | US | disclosed |
| WO-2025078568-A1 | BETA-LACTAMASE SUBSTRATE COMPOUNDS AND ELECTROCHEMICAL DETECTION METHODS USING THEM | CORIS BIOCONCEPT (BE) | 2025-04-17 | — | — | WO | disclosed |
| CN-114728008-A | Compounds for identifying beta-lactamases and methods of use thereof | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022133519-A1 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | CSL Innovation Pty Ltd (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-20220186287-A1 | NOVEL LUCIFERASE SEQUENCES UTILIZING INFRARED-EMITTING SUBSTRATES TO PRODUCE ENHANCED LUMINESCENCE | PROMEGA CORPORATION | 2022-06-16 | — | — | US | disclosed |
| WO-2022115914-A1 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | CSL INNOVATION (AU) | 2022-06-09 | — | — | WO | disclosed |
| EP-3997240-A1 | METHODS FOR DETERMINING THE CONCENTRATION OF A CARBAPENEM ANTIBIOTIC IN A BIOLOGICAL SAMPLE | Université de Liège (BE) | 2022-05-18 | — | — | EP | disclosed |
| US-20220125812-A1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | disclosed |
| EP-3981883-A1 | METHODS FOR DETERMINING ANTIBIOTIC RESISTANCE IN MICROORGANISMS | Erasmus University Medical Center Rotterdam (NL) | 2022-04-13 | — | — | EP | disclosed |
| US-11293047-B2 | Luciferase sequences utilizing infrared-emitting substrates to produce enhanced luminescence | PROMEGA CORPORATION (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3946732-A1 | MICRODROPLET RETENTION ARRANGEMENT | Leibniz-Institut für Photonische Technologien e.V. (DE) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125812-A1 | COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF | BCHE, LCT, BPGM | NR4A2 4528/4885CRHBP 4053/4885CRHR2 4871/4885 |
| US-20250281465-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | ORAI1, CHERP, CASR | NR4A2 3680/4885CRHBP 1103/4885CRHR2 2861/4885 |
| US-12544395-B2 | Combination compositions comprising a beta-lactamase inhibitor and uses thereof | LCT, CTRC, CPN1 | NR4A2 4473/4885CRHBP 3962/4885CRHR2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.